Oxford Biomedica (LON:OXB) Shares Up 12.5% - What's Next?

Key Points

• Oxford Biomedica's shares increased by 12.5% after trading at GBX 497.08 ($6.74), marking a significant rise from its previous close of GBX 439.50 ($5.96).
• Analysts have mixed opinions, with JPMorgan reducing the target price from GBX 490 ($6.64) to GBX 400 ($5.42), while Peel Hunt maintains a "buy" rating with a target of GBX 451 ($6.11).
• Insider Heather Preston bought 11,389 shares at GBX 324 ($4.39), indicating confidence in the company as insiders own 21.17% of the stock.

Oxford Biomedica plc (LON:OXB - Get Free Report) shot up 12.5% during trading on Saturday . The stock traded as high as GBX 497.08 ($6.69) and last traded at GBX 494.50 ($6.65). 566,818 shares changed hands during trading, an increase of 151% from the average session volume of 225,505 shares. The stock had previously closed at GBX 439.50 ($5.91).

Analyst Ratings Changes

OXB has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price target on Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating for the company in a report on Tuesday, July 15th. Peel Hunt reissued a "buy" rating and set a GBX 451 price target on shares of Oxford Biomedica in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of GBX 410.33.

Oxford Biomedica Stock Up 6.6%

The firm has a market cap of £568.71 million, a PE ratio of -3.97 and a beta of 1.09. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. The company has a 50-day simple moving average of GBX 382.84 and a 200-day simple moving average of GBX 337.97.

Insider Buying and Selling

In related news, insider Roch Doliveux bought 67,000 shares of the company's stock in a transaction on Friday, August 15th. The shares were acquired at an average price of GBX 450 per share, with a total value of £301,500. Also, insider Heather Preston acquired 11,389 shares of the firm's stock in a transaction that occurred on Tuesday, June 17th. The shares were bought at an average price of GBX 324 per share, with a total value of £36,900.36. Insiders own 21.17% of the company's stock.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.